CD30/NN
ligation/NN
induces/VBZ
nuclear/JJ
factor-kappa/NN
B/NN
activation/NN
in/IN
human/JJ
T/NN
cell/NN
lines/NNS
./.

CD30/NN
is/VBZ
a/DT
recently/RB
described/VBN
member/NN
of/IN
the/DT
tumor/NN
necrosis/NN
factor/nerve/NN
growth/NN
factor/NN
receptor/NN
superfamily/NN
./.
=====
In/IN
this/DT
report/NN
,/,
we/PRP
show/VBP
that/IN
following/VBG
incubation/NN
of/IN
L540/NN
cells/NNS
(/(
Hodgkin/NN
's/POS
disease-derived/JJ
,/,
T/NN
cell-like/JJ
,/,
CD30+/JJ
cells/NNS
)/)
with/IN
the/DT
agonistic/JJ
anti-CD30/JJ
monoclonal/JJ
antibodies/NNS
(/(
mAb/NN
)/)
M44/NN
and/CC
M67/NN
,/,
two/CD
nuclear/JJ
factor/NN
(/(
NF/NN
)/)
-kappa/NN
B/NN
DNA/NN
binding/NN
activities/NNS
were/VBD
induced/VBN
in/IN
nuclear/JJ
extracts/NNS
,/,
as/IN
determined/VBN
in/IN
gel/NN
retardation/NN
assays/NNS
./.
=====
The/DT
effect/NN
of/IN
the/DT
mAb/NN
towards/IN
NF-kappa/NN
B/NN
activation/NN
was/VBD
rapid/JJ
,/,
as/IN
it/PRP
occurred/VBD
within/IN
20/CD
min/NN
,/,
and/CC
was/VBD
sustained/JJ
for/IN
up/RB
to/TO
6/CD
h/NN
./.
=====
By/IN
comparison/NN
,/,
an/DT
isotype-matched/JJ
antibody/NN
had/VBD
no/DT
effect/NN
on/IN
NF-kappa/NN
B/NN
activation/NN
./.
=====
Moreover/RB
,/,
in/IN
human/JJ
T/NN
helper/NN
(/(
Th/NN
)/)
clones/NNS
functionally/RB
characterized/VBN
as/IN
being/VBG
of/IN
the/DT
type/NN
0/CD
,/,
type/NN
1/CD
and/CC
type/NN
2/CD
(/(
28/CD
%/NN
,/,
</JJR
1/CD
%/NN
und/CC
93/CD
%/NN
CD30+/JJ
,/,
respectively/RB
)/)
,/,
the/DT
extent/NN
of/IN
CD30-mediated/JJ
NF-kappa/NN
B/NN
activation/NN
correlated/VBD
with/IN
the/DT
proportion/NN
of/IN
CD30+/JJ
cells/NNS
./.
=====
In/IN
all/DT
cell/NN
lines/NNS
investigated/VBN
,/,
the/DT
NF-kappa/NN
B/NN
complexes/NNS
induced/VBN
following/VBG
CD30/NN
engagement/NN
were/VBD
shown/VBN
to/TO
contain/VB
p50/NN
NF-kappa/NN
B1/NN
,/,
p65/NN
RelA/NN
,/,
and/CC
possibly/RB
other/JJ
transcription/NN
factors/NNS
./.
=====
Collectively/RB
,/,
our/PRP$
results/NNS
demonstrate/VBP
that/IN
nuclear/JJ
translocation/NN
and/CC
activation/NN
of/IN
NF-kappa/NN
B/NN
rank/NN
among/IN
the/DT
short-term/JJ
cellular/JJ
responses/NNS
elicited/VBD
following/VBG
CD30/NN
ligation/NN
./.